The CDC already recommends the RSV shot for all adults 75 and older and for people 60 and older who have health conditions that increase their risk of severe RSV.

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory syncytial virus (RSV) is associated with a 29% reduction in dementia risk ...

RSV is the leading cause of hospitalizations among newborns and younger children. Among those under age 5, the CDC reports between 58,000 and 80,000 hospitalizations a year. RFK Jr.'s vaccine ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults ages 18 to 59 who are at high risk of severe illness if they ...

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

U.S. vaccine advisers will discuss recommendations for flu vaccines containing the preservative thimerosal and a combination measles shot for children this month, putting topics of concern to ...

GSK’s Arexvy and Pfizer’s Abrysvo are the top-selling RSV vaccines for older adults and will be joined in the next RSV season by Moderna’s recently approved mRESVIA. Meanwhile, Sanofi and AZ ...

By Daniel Papp Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased ...